Dane Leone
Stock Analyst at Raymond James
(1.23)
# 3,636
Out of 5,182 analysts
69
Total ratings
33.96%
Success rate
-5.13%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $13.48 | +40.95% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $84 → $56 | $8.50 | +558.82% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $8.80 | +411.36% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $96.29 | -68.84% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $760.27 | +24.96% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.25 | +477.78% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $71.93 | -36.05% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $28.93 | +138.51% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $5.31 | +50.66% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $8.34 | +67.87% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $12.31 | +371.16% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $12.65 | +453.36% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.62 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $65.48 | -3.79% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $57.67 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.55 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $68.76 | -5.47% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $340.00 | -25.00% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $3.96 | +708.08% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $238.41 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $13.48
Upside: +40.95%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $84 → $56
Current: $8.50
Upside: +558.82%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $8.80
Upside: +411.36%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $96.29
Upside: -68.84%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $760.27
Upside: +24.96%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.25
Upside: +477.78%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $71.93
Upside: -36.05%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $28.93
Upside: +138.51%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $5.31
Upside: +50.66%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $8.34
Upside: +67.87%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $12.31
Upside: +371.16%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $12.65
Upside: +453.36%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.62
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $65.48
Upside: -3.79%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $57.67
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.55
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $68.76
Upside: -5.47%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $340.00
Upside: -25.00%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $3.96
Upside: +708.08%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $238.41
Upside: -